Quinine: Difference between revisions
(Replace manual dosing with dynamic SMW tables) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 1: | Line 1: | ||
== | ==Administration== | ||
*Type: [[ | *Type: Atypical [[antipsychotic]] | ||
*Dosage Forms: | *Dosage Forms: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; 1mg/mL | ||
*Common Trade Names: | *Routes of Administration: Oral, IM | ||
*Common Trade Names: Risperdal | |||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Schizophrenia]]=== | |||
*<65 yo, 1st episode | |||
**1-3 mg/day PO divided qd/bid | |||
***Max: 16mg/day | |||
*<65 yo, maintenance | |||
**1-4 mg/day PO divided qd/bid | |||
*65+ yo | |||
**1-4 mg/day PO divided qd/bid | |||
***Doses >4 mg/day rarely more effective | |||
===[[Bipolar disorder]], Type 1, Acute manic=== | |||
*1-6 mg/day PO divided qd/bid | |||
**Max: 6 mg/day | |||
===Tourette Syndrome=== | |||
*0.25-3 mg/day PO divided qd-bid | |||
**Max 6 mg/day | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Quinine]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Quinine]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Pediatric procedural sedation=== | |||
*0.01mg/kg/dose IM (typically 0.25-4mg/dose) | |||
===[[Schizophrenia]]=== | |||
*1-6 mg/day PO divided qd/bid | |||
===[[Bipolar disorder]], Type 1, Acute mania=== | |||
*0.5-6mg/day PO divided qd/bid | |||
===Irritability, Autistic disorder associated=== | |||
*0.5-3 mg/day PO divided qd/bid | |||
===Tourrette syndrome=== | |||
*0.75-3 mg/day PO divided qd/bid | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Quinine]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Quinine]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | ||
*Renal | *Renal: | ||
**Adult | **Adult: | ||
*** | ***CrCl <30: Start 0.5 mg BID then increase by 0.5mg BID weekly | ||
*** | ***HD: Not defined | ||
**Pediatric | **Pediatric: | ||
***Not defined | ***Not defined, see adult dosing. | ||
*Hepatic | *Hepatic: | ||
**Adult | **Adult: | ||
*** | ***Child-Pugh Class C: Start 0.5 mg BID and increase by 0.5mg BID weekly | ||
*** | **Pediatric: | ||
***Not defined, see adult dosing. | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
* | *Caution: | ||
* | **Pediatric/adolescent pts | ||
* | **Pregnancy 3rd trimester | ||
* | **Elderly pts | ||
* | **Dementia-related psychosis | ||
* | **Renal impairment | ||
* | **Hepatic impairment | ||
* | **Parkinson's Disease | ||
* | **[[Neuroleptic malignant syndrome]] history | ||
* | **Seizure history | ||
* | **Cardiovascular disease | ||
*[[ | **[[Diabetes mellitus]] | ||
* | **Suicide risk | ||
* | |||
*[[ | |||
* | |||
* | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* | *[[Hypotension]], [[syncope]] | ||
*Extrapyramidal symptoms: [[tardive dyskinesia]] | |||
*[[ | *[[Neuroleptic malignant syndrome]], [[hyperthermia]] | ||
*[[ | *[[Hyperglycemia]], [[diabetes mellitus]], [[DKA]] | ||
*[[Seizure]], [[Priapism]], [[Stroke]], [[TIA]] | |||
*Dysphagia | |||
*[[ | *[[Leukopenia]], [[Neutropenia]], [[Agranulocytosis]] | ||
*Suicidality | |||
* | *[[Pancreatitis]] | ||
*[[ | |||
* | |||
* | |||
===Common=== | ===Common=== | ||
* | *Akathisia, dystonia, parkinsonism, tremor | ||
* | *Sedation/[[fatigue]], [[dizziness]], blurred vision, [[anxiety]], confusion | ||
* | *[[Rash]] | ||
* | *Hyperprolactinemia, weight gain, increased appetite | ||
* | *[[Constipation]], [[diarrhea]], [[nausea]]/[[vomiting]] | ||
*Urinary incontinence | |||
*[[Cough]], URI | |||
* | *[[Photosensitivity]], visual disturbance | ||
*[[ | |||
* | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 20h (PO); 3-6 day (IM) | ||
*Metabolism: | *Metabolism: Hepatic, CYP2D6 | ||
*Excretion: Urine | *Excretion: Urine 70%, Feces 14% | ||
== | ==Mechanism of Action== | ||
* | *Unknown | ||
*5HT-2 inhibitor, weaker D2 inhibitor | |||
== | ==Comments== | ||
==See Also== | ==See Also== | ||
[[Antipsychotics]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Psychiatry]] | ||
Revision as of 02:39, 20 March 2026
Administration
- Type: Atypical antipsychotic
- Dosage Forms: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; 1mg/mL
- Routes of Administration: Oral, IM
- Common Trade Names: Risperdal
Adult Dosing
Schizophrenia
- <65 yo, 1st episode
- 1-3 mg/day PO divided qd/bid
- Max: 16mg/day
- 1-3 mg/day PO divided qd/bid
- <65 yo, maintenance
- 1-4 mg/day PO divided qd/bid
- 65+ yo
- 1-4 mg/day PO divided qd/bid
- Doses >4 mg/day rarely more effective
- 1-4 mg/day PO divided qd/bid
Bipolar disorder, Type 1, Acute manic
- 1-6 mg/day PO divided qd/bid
- Max: 6 mg/day
Tourette Syndrome
- 0.25-3 mg/day PO divided qd-bid
- Max 6 mg/day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Babesiosis | 650mg TID | Severe parasitemia with Clindamycin use IV for severe |
| Malaria | 648mg PO q8h x 7 days | Uncomplicated malaria, use with doxycycline or clindamycin |
Pediatric Dosing
Pediatric procedural sedation
- 0.01mg/kg/dose IM (typically 0.25-4mg/dose)
Schizophrenia
- 1-6 mg/day PO divided qd/bid
Bipolar disorder, Type 1, Acute mania
- 0.5-6mg/day PO divided qd/bid
Irritability, Autistic disorder associated
- 0.5-3 mg/day PO divided qd/bid
Tourrette syndrome
- 0.75-3 mg/day PO divided qd/bid
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Babesiosis | 8mg/kg PO q8h x 7-10 days (Max: 648mg/dose) | Severe parasitemia with Clindamycin |
| Malaria | 30mg/kg/day PO q8h x 3-7 days (Max: 648mg/dose) | Uncomplicated malaria, use with clindamycin |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal:
- Adult:
- CrCl <30: Start 0.5 mg BID then increase by 0.5mg BID weekly
- HD: Not defined
- Pediatric:
- Not defined, see adult dosing.
- Adult:
- Hepatic:
- Adult:
- Child-Pugh Class C: Start 0.5 mg BID and increase by 0.5mg BID weekly
- Pediatric:
- Not defined, see adult dosing.
- Adult:
Contraindications
- Allergy to class/drug
- Caution:
- Pediatric/adolescent pts
- Pregnancy 3rd trimester
- Elderly pts
- Dementia-related psychosis
- Renal impairment
- Hepatic impairment
- Parkinson's Disease
- Neuroleptic malignant syndrome history
- Seizure history
- Cardiovascular disease
- Diabetes mellitus
- Suicide risk
Adverse Reactions
Serious
- Hypotension, syncope
- Extrapyramidal symptoms: tardive dyskinesia
- Neuroleptic malignant syndrome, hyperthermia
- Hyperglycemia, diabetes mellitus, DKA
- Seizure, Priapism, Stroke, TIA
- Dysphagia
- Leukopenia, Neutropenia, Agranulocytosis
- Suicidality
- Pancreatitis
Common
- Akathisia, dystonia, parkinsonism, tremor
- Sedation/fatigue, dizziness, blurred vision, anxiety, confusion
- Rash
- Hyperprolactinemia, weight gain, increased appetite
- Constipation, diarrhea, nausea/vomiting
- Urinary incontinence
- Cough, URI
- Photosensitivity, visual disturbance
Pharmacology
- Half-life: 20h (PO); 3-6 day (IM)
- Metabolism: Hepatic, CYP2D6
- Excretion: Urine 70%, Feces 14%
Mechanism of Action
- Unknown
- 5HT-2 inhibitor, weaker D2 inhibitor
